Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2B | P29275 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 11/20 | 0.37 |
| ▸ | ATR | Q13535 | 4/20 | 0.37 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.36 |
| ▸ | GSK3B | P49841 | 2/20 | 0.34 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.33 |
| ▸ | MTOR | P42345 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4184831 | 0.84 | HSD17B10 (0.39) | HSD17B10HPGDHTTATMATR | |
| SCHEMBL23620552 | 0.82 | HPGD (0.56) | ADORA2BHSD17B10HPGDHTTGSK3B | |
| SCHEMBL28722266 | 0.81 | HPGD (0.37) | HSD17B10HPGDHTTATMATR | |
| SCHEMBL25057366 | 0.78 | HSD17B10 (0.44) | ADORA2BHSD17B10HPGDHTTGSK3B | |
| SCHEMBL30328166 | 0.74 | HPGD (0.38) | HSD17B10HPGDHTT | |
| SCHEMBL10006721 | 0.74 | HPGD (0.38) | HSD17B10HPGDHTT | |
| SCHEMBL24851745 | 0.73 | HSD17B10 (0.42) | ADORA2BHSD17B10HPGDHTTATM | |
| SCHEMBL30162061 | 0.73 | HSD17B10 (0.42) | ADORA2BHSD17B10HPGDHTTATM | |
| SCHEMBL29651071 | 0.72 | GSK3B (0.64) | HSD17B10HPGDHTTGSK3BPIK3CA | |
| SCHEMBL28821218 | 0.71 | PRKDC (0.43) | HSD17B10HPGDHTTPIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110118238-A1 | 2-ANILINOPURIN-8-ONES AS INHIBITORS OF TTK/MPS1 FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | ASTRAZENECA AB (SE) | 2011-05-19 | — | — | US | disclosed |
| EP-2212326-A1 | 2-ANILINOPURIN-8-ONES AS INHIBITORS OF TTK/MPS1 FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | AstraZeneca AB (SE) | 2010-08-04 | — | — | EP | disclosed |
| WO-2009024824-A1 | 2-ANILINOPURIN-8-ONES AS INHIBITORS OF TTK/MPS1 FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | ASTRAZENECA AB (SE) | 2009-02-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110118238-A1 | 2-ANILINOPURIN-8-ONES AS INHIBITORS OF TTK/MPS1 FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | BUB1, BUB1B, TTBK1 | ADORA2B 4183/4885HSD17B10 4313/4885HPGD 4223/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.